By Iain Gilbert
Date: Thursday 31 Jul 2025
(Sharecast News) - Consumer healthcare company Haleon hiked its interim dividend and raised its FY profit outlook on Wednesday after posting increased adjusted operating profits for H1, driven by productivity gains and margin expansion, but pared back its organic revenue growth forecast.
Holding(s) in Company | 31-Jul-2025 | 17:33 | RNS |
Holding(s) in Company | 31-Jul-2025 | 17:28 | RNS |
Total Voting Rights | 31-Jul-2025 | 16:30 | RNS |
Holding(s) in Company | 31-Jul-2025 | 15:24 | RNS |
Interim Results for the 12 months to 31 March 2025 | 31-Jul-2025 | 12:30 | RNS |
Questor :GW Pharmaceuticals | 04-Dec-2014 | Telegraph |
Questor : Hikma Pharmaceuticals | 13-Mar-2014 | Telegraph |
Investment Column:BTG | 06-Oct-2011 | The Independent |
Investment Column:Genus | 09-Sep-2011 | The Independent |
Questor :Dechra Pharmaceuticals | 08-Sep-2011 | Telegraph |
Price | 21,307.63 |
Closing Price Change | -395.95 |
% Change | -1.82 % |
31-Jul-25 Close | 21,307.63 |
You are here: research